Base de dados : MEDLINE
Pesquisa : D03.383.129.308.550 [Categoria DeCS]
Referências encontradas : 1924 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 193 ir para página                         

  1 / 1924 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28566666
[Au] Autor:Sakaguchi H
[Ad] Endereço:Director of Dental Practice, Ryohoku Hospital.
[Ti] Título:Treatment and Prevention of Oral Candidiasis in Elderly Patients.
[So] Source:Med Mycol J;58(2):J43-J49, 2017.
[Is] ISSN:1882-0476
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:The incidence of oral candidiasis has increased in the elderly in recent years. Although the increase of the elderly population plays a big role in this rise of oral candidiasis, the broader recognition that elderly people have higher infection rates for oral candidiasis is considered to be also an important factor. Oral candidiasis can be categorized into three types. Pseudomembranous oral candidiasis is characterized by the appearance of white moss, erythematous oral candidiasis by the eruption of erythema, and hyperplastic oral candidiasis by mucosal hyperplasia. Miconazole has been commonly used when treating oral candidiasis. Elderly patients, however, have a tendency to develop oral candidiasis repeatedly. It is therefore critical to take measures to prevent recurrence. We recommend the use an oral moisturizer containing hinokitiol, an antifungal substance, on a regular basis, to help prevent recurrence of oral candidiasis.
[Mh] Termos MeSH primário: Candidíase Bucal/tratamento farmacológico
Candidíase Bucal/prevenção & controle
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Antifúngicos/administração & dosagem
Candidíase Bucal/classificação
Candidíase Bucal/patologia
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Miconazol/administração & dosagem
Monoterpenos/administração & dosagem
Recidiva
Prevenção Secundária
Tropolona/administração & dosagem
Tropolona/análogos & derivados
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Monoterpenes); 7L6DL16P1T (Tropolone); 7NNO0D7S5M (Miconazole); U5335D6EBI (beta-thujaplicin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171015
[Lr] Data última revisão:
171015
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170602
[St] Status:MEDLINE
[do] DOI:10.3314/mmj.17.004


  2 / 1924 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28346211
[Au] Autor:Gautam P; Light B; Purvis T
[Ad] Endereço:HUMCO Research and Development Laboratory, Austin, Texas. pgautam@humco.com.
[Ti] Título:Stability of Two Antifungal Agents, Fluconazole and Miconazole, Compounded in HUMCO RECURA Topical Cream to Determine Beyond-Use Date.
[So] Source:Int J Pharm Compd;21(2):154-159, 2017 Mar-Apr.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A novel compounding vehicle (RECURA) has previously been proven to penetrate the nail bed when compounded with the antifungal agent miconazole or fluconazole, providing for an effective treatment for onychomycosis. In this study, miconazole and fluconazole were compounded separately in RECURA compounding cream, and they were tested at different time points (0, 7, 14, 28, 45, 60, 90, and 180 days) to determine the beyond-use date of those formulations. The beyond-use date testing of both formulations (10% miconazole in RECURA and 10% fluconazole in RECURA) proved them to be physically, chemically, and microbiologically stable under International Conference of Harmonisation controlled room temperature (25°C ± 2°C/60% RH ±5%) for at least 180 days from the date of compounding. Stability-indicating analytical method validation was completed for the simultaneous determination of miconazole and fluconazole in RECURA base using high-performance liquid chromatography coupled with photodiode array detector prior to the study.
[Mh] Termos MeSH primário: Antifúngicos/química
Fluconazol/química
Miconazol/química
[Mh] Termos MeSH secundário: Administração Tópica
Antifúngicos/administração & dosagem
Cromatografia Líquida de Alta Pressão
Composição de Medicamentos
Estabilidade de Medicamentos
Armazenamento de Medicamentos
Fluconazol/administração & dosagem
Umidade
Miconazol/administração & dosagem
Pomadas
Temperatura Ambiente
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Ointments); 7NNO0D7S5M (Miconazole); 8VZV102JFY (Fluconazole)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170619
[Lr] Data última revisão:
170619
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE


  3 / 1924 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28248999
[Au] Autor:Van den Driessche F; Vanhoutte B; Brackman G; Crabbé A; Rigole P; Vercruysse J; Verstraete G; Cappoen D; Vervaet C; Cos P; Coenye T
[Ad] Endereço:Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.
[Ti] Título:Evaluation of combination therapy for Burkholderia cenocepacia lung infection in different in vitro and in vivo models.
[So] Source:PLoS One;12(3):e0172723, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Burkholderia cenocepacia is an opportunistic pathogen responsible for life-threatening infections in cystic fibrosis patients. B. cenocepacia is extremely resistant towards antibiotics and therapy is complicated by its ability to form biofilms. We investigated the efficacy of an alternative antimicrobial strategy for B. cenocepacia lung infections using in vitro and in vivo models. A screening of the NIH Clinical Collection 1&2 was performed against B. cenocepacia biofilms formed in 96-well microtiter plates in the presence of tobramycin to identify repurposing candidates with potentiator activity. The efficacy of selected hits was evaluated in a three-dimensional (3D) organotypic human lung epithelial cell culture model. The in vivo effect was evaluated in the invertebrate Galleria mellonella and in a murine B. cenocepacia lung infection model. The screening resulted in 60 hits that potentiated the activity of tobramycin against B. cenocepacia biofilms, including four imidazoles of which econazole and miconazole were selected for further investigation. However, a potentiator effect was not observed in the 3D organotypic human lung epithelial cell culture model. Combination treatment was also not able to increase survival of infected G. mellonella. Also in mice, there was no added value for the combination treatment. Although potentiators of tobramycin with activity against biofilms of B. cenocepacia were identified in a repurposing screen, the in vitro activity could not be confirmed nor in a more sophisticated in vitro model, neither in vivo. This stresses the importance of validating hits resulting from in vitro studies in physiologically relevant model systems.
[Mh] Termos MeSH primário: Biofilmes/efeitos dos fármacos
Infecções por Burkholderia/tratamento farmacológico
Burkholderia cenocepacia/fisiologia
Econazol/farmacologia
Miconazol/farmacologia
Pneumonia Bacteriana/tratamento farmacológico
Tobramicina/farmacologia
[Mh] Termos MeSH secundário: Células A549
Animais
Biofilmes/crescimento & desenvolvimento
Infecções por Burkholderia/metabolismo
Infecções por Burkholderia/patologia
Modelos Animais de Doenças
Avaliação Pré-Clínica de Medicamentos
Quimioterapia Combinada/métodos
Feminino
Seres Humanos
Camundongos
Camundongos Endogâmicos BALB C
Pneumonia Bacteriana/metabolismo
Pneumonia Bacteriana/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
6Z1Y2V4A7M (Econazole); 7NNO0D7S5M (Miconazole); VZ8RRZ51VK (Tobramycin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0172723


  4 / 1924 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28189133
[Au] Autor:Gómez Moyano E; Martínez Pilar L; Martinez Garcia S; Simonsen S
[Ti] Título:Multiple hyperpigmented patches on a dark-skinned patient.
[So] Source:Aust Fam Physician;46(1):48-49, 2017 Jan/Feb.
[Is] ISSN:0300-8495
[Cp] País de publicação:Australia
[La] Idioma:eng
[Mh] Termos MeSH primário: Hiperpigmentação/etiologia
Miconazol/uso terapêutico
Naftalenos/uso terapêutico
Tinha
[Mh] Termos MeSH secundário: Adulto
Antifúngicos/administração & dosagem
Antifúngicos/uso terapêutico
Diagnóstico Diferencial
Quimioterapia Combinada
Seres Humanos
Masculino
Miconazol/administração & dosagem
Naftalenos/administração & dosagem
Tinha/complicações
Tinha/diagnóstico
Tinha/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Naphthalenes); 7NNO0D7S5M (Miconazole); G7RIW8S0XP (terbinafine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170213
[St] Status:MEDLINE


  5 / 1924 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28105725
[Au] Autor:Ng SM; Yap YY; Cheong JW; Ng FM; Lau QY; Barkham T; Teo JW; Hill J; Chia CS
[Ad] Endereço:Experimental Therapeutics Centre, Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, Nanos #03-01, 138669, Singapore.
[Ti] Título:Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans.
[So] Source:J Pept Sci;23(3):215-221, 2017 Mar.
[Is] ISSN:1099-1387
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Vulvovaginal candidiasis/candidosis is a common fungal infection afflicting approximately 75% of women globally caused primarily by the yeast Candida albicans. Fluconazole is widely regarded as the antifungal drug of choice since its introduction in 1990 due to its high oral bioavailability, convenient dosing regimen and favourable safety profile. However, its widespread use has led to the emergence of fluconazole-resistant C. albicans, posing a universal clinical concern. Coupled to the dearth of new antifungal drugs entering the market, it is imperative to introduce new drug classes to counter this threat. Antimicrobial peptides (AMPs) are potential candidates due to their membrane-disrupting mechanism of action. By specifically targeting fungal membranes and being rapidly fungicidal, they can reduce the chances of resistance development and treatment duration. Towards this goal, we conducted a head-to-head comparison of 61 short linear AMPs from the literature to identify the peptide with the most potent activity against fluconazole-resistant C. albicans. The 11-residue peptide, P11-6, was identified and assayed against a panel of clinical C. albicans isolates followed by fungicidal/static determination and a time-kill assay to gauge its potential for further drug development. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Antifúngicos/síntese química
Peptídeos Catiônicos Antimicrobianos/síntese química
Candida albicans/efeitos dos fármacos
Farmacorresistência Fúngica/efeitos dos fármacos
[Mh] Termos MeSH secundário: Ágar
Sequência de Aminoácidos
Antifúngicos/farmacologia
Peptídeos Catiônicos Antimicrobianos/farmacologia
Candida albicans/crescimento & desenvolvimento
Candida albicans/isolamento & purificação
Candidíase Vulvovaginal/microbiologia
Feminino
Fluconazol/farmacologia
Seres Humanos
Miconazol/farmacologia
Testes de Sensibilidade Microbiana
Relação Quantitativa Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Antimicrobial Cationic Peptides); 7NNO0D7S5M (Miconazole); 8VZV102JFY (Fluconazole); 9002-18-0 (Agar)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170307
[Lr] Data última revisão:
170307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170121
[St] Status:MEDLINE
[do] DOI:10.1002/psc.2970


  6 / 1924 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28007924
[Au] Autor:Balkus JE; Srinivasan S; Anzala O; Kimani J; Andac C; Schwebke J; Fredricks DN; McClelland RS
[Ad] Endereço:Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center , Seattle, Washington, USA.
[Ti] Título:Impact of Periodic Presumptive Treatment for Bacterial Vaginosis on the Vaginal Microbiome among Women Participating in the Preventing Vaginal Infections Trial.
[So] Source:J Infect Dis;215(5):723-731, 2017 03 01.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Evidence suggests that specific vaginal bacteria associated with bacterial vaginosis (BV) may increase the risk of adverse health outcomes in women. Among women participating in a randomized, double-blinded trial, we assessed the effect of periodic presumptive treatment (PPT) on detection of select vaginal bacteria. Methods: High-risk women from the United States and Kenya with a recent vaginal infection received intravaginal metronidazole 750 mg plus miconazole 200 mg or placebo for 5 consecutive nights each month for 12 months. Vaginal fluid specimens were collected via polyester/polyethylene terephthalate swabs every other month and tested for bacteria, using quantitative polymerase chain reaction (PCR) assays targeting the 16S ribosomal RNA gene. The effect of PPT on bacterium detection was assessed among all participants and stratified by country. Results: Of 234 women enrolled, 221 had specimens available for analysis. The proportion of follow-up visits with detectable quantities was lower in the PPT arm versus the placebo arm for the following bacteria: BVAB1, BVAB2, Atopobium vaginae, Leptotrichia/Sneathia, and Megasphaera. The magnitude of reductions was greater among Kenyan participants as compared to US participants. Conclusions: Use of monthly PPT for 1 year reduced colonization with several bacteria strongly associated with BV. The role of PPT to improve vaginal health should be considered, and efforts to improve the impact of PPT regimens are warranted.
[Mh] Termos MeSH primário: Metronidazol/administração & dosagem
Miconazol/administração & dosagem
Microbiota
Vagina/microbiologia
Vaginose Bacteriana/tratamento farmacológico
[Mh] Termos MeSH secundário: Actinobacteria/efeitos dos fármacos
Actinobacteria/isolamento & purificação
Administração Tópica
Adolescente
Adulto
Anti-Infecciosos/administração & dosagem
Anti-Infecciosos/uso terapêutico
Relação Dose-Resposta a Droga
Método Duplo-Cego
Feminino
Seguimentos
Seres Humanos
Quênia
Lactobacillus/efeitos dos fármacos
Lactobacillus/isolamento & purificação
Leptotrichia/efeitos dos fármacos
Leptotrichia/isolamento & purificação
Limite de Detecção
Modelos Lineares
Megasphaera/efeitos dos fármacos
Megasphaera/isolamento & purificação
Metronidazol/uso terapêutico
Miconazol/uso terapêutico
Meia-Idade
Manejo de Espécimes
Vaginose Bacteriana/prevenção & controle
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Infective Agents); 140QMO216E (Metronidazole); 7NNO0D7S5M (Miconazole)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170715
[Lr] Data última revisão:
170715
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161224
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jiw622


  7 / 1924 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27901310
[Au] Autor:Hellfritzsch M; Pottegård A; Pedersen AJ; Burghle A; Mouaanaki F; Hallas J; Grove EL; Damkier P
[Ad] Endereço:Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
[Ti] Título:Topical Antimycotics for Oral Candidiasis in Warfarin Users.
[So] Source:Basic Clin Pharmacol Toxicol;120(4):368-372, 2017 Apr.
[Is] ISSN:1742-7843
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Treatment for oral candidiasis in warfarin users may be complicated by drug-drug interactions (DDIs) between warfarin and topically applied antimycotics. However, current knowledge of these putative DDIs is merely based on case series. We therefore performed a cohort cross-over study with the objective to evaluate the potential DDIs between warfarin and miconazole oral gel or nystatin oral solution. The cohort consisted of individuals using warfarin in the period of 1998-2012 (n ≈ 7400). We collected data on cohort members' measurements of the international normalized ratio (INR) from a clinical database, and obtained information on their use of topically applied miconazole and nystatin from a regional prescription register. Potential DDIs were assessed by comparing INR values before and after initiation of an antimycotic drug. Among 17 warfarin users exposed to miconazole oral gel, the mean INR increased from 2.5 (95% CI: 2.1-2.8) to 3.8 (95% CI: 2.8-4.8) after exposure, corresponding to a mean INR increase of 1.4 (95% CI: 0.3-2.4). Among 30 warfarin users exposed to nystatin oral solution, the mean INR was 2.7 (95% CI: 2.3-3.1) before and 2.5 (95% CI: 2.2-2.9) after exposure. In conclusion, we found evidence supporting a clinically relevant drug-drug interaction between warfarin and miconazole oral gel. In contrast, we did not find any indication of an interaction between warfarin and nystatin oral solution. Nystatin rather than miconazole should be preferred when treating warfarin users for oral candidiasis.
[Mh] Termos MeSH primário: Antifúngicos/efeitos adversos
Coagulação Sanguínea/efeitos dos fármacos
Candidíase Bucal/tratamento farmacológico
Miconazol/efeitos adversos
Nistatina/efeitos adversos
Varfarina/efeitos adversos
[Mh] Termos MeSH secundário: Administração Oral
Idoso
Antifúngicos/administração & dosagem
Antifúngicos/uso terapêutico
Candidíase Bucal/sangue
Estudos de Coortes
Estudos Cross-Over
Interações Medicamentosas
Feminino
Géis
Seres Humanos
Coeficiente Internacional Normatizado
Masculino
Miconazol/administração & dosagem
Miconazol/uso terapêutico
Meia-Idade
Nistatina/administração & dosagem
Nistatina/uso terapêutico
Soluções
Varfarina/administração & dosagem
Varfarina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Gels); 0 (Solutions); 1400-61-9 (Nystatin); 5Q7ZVV76EI (Warfarin); 7NNO0D7S5M (Miconazole)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170324
[Lr] Data última revisão:
170324
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161201
[St] Status:MEDLINE
[do] DOI:10.1111/bcpt.12722


  8 / 1924 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27865736
[Au] Autor:Nicaise AM; Banda E; Guzzo RM; Russomanno K; Castro-Borrero W; Willis CM; Johnson KM; Lo AC; Crocker SJ
[Ad] Endereço:Department of Neuroscience, University of Connecticut School of Medicine, 263 Farmington Ave., Farmington, CT 06032, United States.
[Ti] Título:iPS-derived neural progenitor cells from PPMS patients reveal defect in myelin injury response.
[So] Source:Exp Neurol;288:114-121, 2017 Feb.
[Is] ISSN:1090-2430
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Primary progressive multiple sclerosis (PPMS) is a chronic demyelinating disease of the central nervous system (CNS) currently lacking any effective treatment. Promoting endogenous brain repair offers a potential strategy to halt and possibly restore neurologic function in PPMS. To understand how the microenvironment within white matter lesions plays a role in repair we have focused on neural progenitor cells (NPCs) since these are found in lesions in PPMS and have been found to influence oligodendrocyte progenitor cell maturation (OPCs). To better understand the cellular nature of NPCs in PPMS we developed iPS cells from blood samples of PPMS patients and age matched non-disease spouse or blood relative controls. Using these iPS cell lines we determined that the NPCs from PPMS cases provided no neuroprotection against active CNS demyelination compared to NPCs from control iPS lines which were capable of completely preventing injury. Conditioned media (CM) from PPMS NPCs provides no protection to OPCs and prevents maturation of OPCs into oligodendrocytes in vitro. We also found that CM from PPMS iPS NPCs elicited patient-specific differences in the response to compounds that should foster oligodendrocyte (OL) maturation. Together, these data establish a new model for understanding the nature of myelination defects in PPMS which may lead to novel targeted approaches for preventing demyelination in these patients.
[Mh] Termos MeSH primário: Células-Tronco Pluripotentes Induzidas/patologia
Esclerose Múltipla Crônica Progressiva/patologia
Bainha de Mielina/patologia
[Mh] Termos MeSH secundário: Idoso
Animais
Apoptose/efeitos dos fármacos
Axônios/patologia
Axônios/ultraestrutura
Diferenciação Celular/efeitos dos fármacos
Clemastina/farmacologia
Clemastina/uso terapêutico
Meios de Cultivo Condicionados/farmacologia
Cuprizona/toxicidade
Feminino
Seres Humanos
Células-Tronco Pluripotentes Induzidas/química
Células-Tronco Pluripotentes Induzidas/efeitos dos fármacos
Células-Tronco Pluripotentes Induzidas/ultraestrutura
Masculino
Camundongos Endogâmicos C57BL
Miconazol/farmacologia
Miconazol/uso terapêutico
Meia-Idade
Inibidores da Monoaminoxidase/toxicidade
Esclerose Múltipla Crônica Progressiva/induzido quimicamente
Proteína Básica da Mielina/metabolismo
Bainha de Mielina/ultraestrutura
Proteínas do Tecido Nervoso/metabolismo
Oligodendroglia/efeitos dos fármacos
Oligodendroglia/patologia
Oligodendroglia/ultraestrutura
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Culture Media, Conditioned); 0 (Mbp protein, mouse); 0 (Monoamine Oxidase Inhibitors); 0 (Myelin Basic Protein); 0 (Nerve Tissue Proteins); 5N16U7E0AO (Cuprizone); 7NNO0D7S5M (Miconazole); 95QN29S1ID (Clemastine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170512
[Lr] Data última revisão:
170512
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161121
[St] Status:MEDLINE


  9 / 1924 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27625339
[Au] Autor:Rojas FD; Córdoba SB; de Los Ángeles Sosa M; Zalazar LC; Fernández MS; Cattana ME; Alegre LR; Carrillo-Muñoz AJ; Giusiano GE
[Ad] Endereço:Departamento de Micología, Instituto de Medicina Regional, Universidad Nacional del Nordeste, Resistencia, Chaco, Argentina.
[Ti] Título:Antifungal susceptibility testing of Malassezia yeast: comparison of two different methodologies.
[So] Source:Mycoses;60(2):104-111, 2017 Feb.
[Is] ISSN:1439-0507
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:All Malassezia species are lipophilic; thus, modifications are required in susceptibility testing methods to ensure their growth. Antifungal susceptibility of Malassezia species using agar and broth dilution methods has been studied. Currently, few tests using disc diffusion methods are being performed. The aim was to evaluate the in vitro susceptibility of Malassezia yeast against antifungal agents using broth microdilution and disc diffusion methods, then to compare both methodologies. Fifty Malassezia isolates were studied. Microdilution method was performed as described in reference document and agar diffusion test was performed using antifungal tablets and discs. To support growth, culture media were supplemented. To correlate methods, linear regression analysis and categorical agreement was determined. The strongest linear association was observed for fluconazole and miconazole. The highest agreement between both methods was observed for itraconazole and voriconazole and the lowest for amphotericin B and fluconazole. Although modifications made to disc diffusion method allowed to obtain susceptibility data for Malassezia yeast, variables cannot be associated through a linear correlation model, indicating that inhibition zone values cannot predict MIC value. According to the results, disc diffusion assay may not represent an alternative to determine antifungal susceptibility of Malassezia yeast.
[Mh] Termos MeSH primário: Antifúngicos/farmacologia
Malassezia/efeitos dos fármacos
[Mh] Termos MeSH secundário: Ágar
Anfotericina B/farmacologia
Meios de Cultura
Fluconazol/farmacologia
Itraconazol/farmacologia
Malassezia/crescimento & desenvolvimento
Miconazol/farmacologia
Testes de Sensibilidade Microbiana/métodos
Voriconazol/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Culture Media); 304NUG5GF4 (Itraconazole); 7NNO0D7S5M (Miconazole); 7XU7A7DROE (Amphotericin B); 8VZV102JFY (Fluconazole); 9002-18-0 (Agar); JFU09I87TR (Voriconazole)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170323
[Lr] Data última revisão:
170323
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160915
[St] Status:MEDLINE
[do] DOI:10.1111/myc.12556


  10 / 1924 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26809882
[Au] Autor:Moriello KA
[Ad] Endereço:Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
[Ti] Título:In vitro efficacy of shampoos containing miconazole, ketoconazole, climbazole or accelerated hydrogen peroxide against Microsporum canis and Trichophyton species.
[So] Source:J Feline Med Surg;19(4):370-374, 2017 Apr.
[Is] ISSN:1532-2750
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives The objective was to evaluate the antifungal efficacy of shampoo formulations of ketoconazole, miconazole or climbazole and accelerated hydrogen peroxide wash/rinse against Microsporum canis and Trichophyton species spores. Methods Lime sulfur (1:16)-treated control, enilconazole (1:100)-treated control, accelerated hydrogen peroxide (AHP 7%) 1:20 and a 1:10 dilution of shampoo formulations of miconazole 2%, miconazole 2%/chlorhexidine gluconate 2-2.3%, ketoconazole 1%/chlorhexidine 2%, climbazole 0.5%/chlorhexidine 3% and sterile water-untreated control were tested in three experiments. In the first, a suspension of infective spores and hair/scale fragments was incubated with a 1:10, 1:5 and 1:1 dilution of spores to test solutions for 10 mins. In the second, toothbrushes containing infected cat hair in the bristles were soaked and agitated in test solutions for 10 mins, rinsed, dried and then fungal cultured (n = 12×). In the third, a 3 min contact time combined with an AHP rinse was tested (n = 10×). Good efficacy was defined as no growth. Results Water controls grew >300 colony-forming units/plate and all toothbrushes were culture-positive prior to testing. For the suspension tests, all test products showed good efficacy. Miconazole 2%, ketoconazole 1% and AHP showed good efficacy after a 10 min contact time. Good efficacy was achieved with a shorter contact time (3 mins) only if combined with an AHP rinse. Conclusions and relevance Lime sulfur and enilconazole continued to show good efficacy. In countries or situations where these products cannot be used, shampoos containing ketoconazole, miconazole or climbazole are alternative haircoat disinfectants, with a 10 min contact time or 3 mins if combined with an AHP rinse.
[Mh] Termos MeSH primário: Doenças do Gato/prevenção & controle
Desinfetantes/farmacologia
Microsporum/efeitos dos fármacos
Tinha/veterinária
Trichophyton/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Doenças do Gato/microbiologia
Gatos
Preparações para Cabelo
Peróxido de Hidrogênio/farmacologia
Imidazóis/farmacologia
Cetoconazol/farmacologia
Miconazol/farmacologia
Tinha/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Disinfectants); 0 (Hair Preparations); 0 (Imidazoles); 7NNO0D7S5M (Miconazole); 9N42CW7I54 (climbazole); BBX060AN9V (Hydrogen Peroxide); R9400W927I (Ketoconazole)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160127
[St] Status:MEDLINE
[do] DOI:10.1177/1098612X15626197



página 1 de 193 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde